Emily Menendez

DocwireNews

Circulating tumor DNA (ctDNA) is commonly used to measure patient prognosis, monitor disease progression, and determine treatment outcomes in patients with cancer. While it is also utilized for early cancer detection, studies of asymptomatic and symptomatic patients have demonstrated lower ctDNA detection in asymptomatic patients.
A recent study <a href="https://www.nature.com/articles/s41416-024-02867-5#Sec15" target="_blank" rel="noopener">published in the British Journal of Cancer</a> analyzed the use of ctDNA assessment in patients with asymptomatic colorectal cancer (CRC) to determine if they differ from symptomatic patients by including “low ctDNA shedding” and “less aggressive” patient subgroups.
ctDNA assessment was carried out in two independent cohorts for each cancer type. The asymptomatic CRC group consisted of 215 patients in cohort 1 and 368 patients in cohort 2, while the symptomatic CRC group consisted of 117 patients in cohort 1 and 722 patients in cohort 2.
When adjusted for tumor stage and size, the detection of ctDNA was significantly lower in asymptomatic patients than in symptomatic patients (Cohort 1: OR: 0.4, 95%CI: 0.2–0.8, Cohort 2: OR: 0.7, 95%CI: 0.5–0.9).
The recurrence risk was also lower in asymptomatic patients (Cohort 1: sHR: 0.6, 95%CI: 0.3–1.2, Cohort 2: sHR: 0.6, 95%CI: 0.4–1.0), with ctDNA-negative asymptomatic patients having the lowest recurrence risk compared to symptomatic patients (Cohort 1: sHR: 0.2, 95%CI: 0.1–0.6, Cohort 2: sHR: 0.3, 95%CI: 0.2–0.6).
Asymptomatic patients may be enriched for “low ctDNA shedding” or “low recurrence risk” subgroups. These insights can help aid in the guidance of ctDNA-based early detection initiatives, and can prompt potential de-escalation of therapy and follow-up for ctDNA-negative asymptomatic CRC patients.

Jordana Jampel

Inconsistent Definitions of Moderate IBD Across Phase 3 Pharmacologic Trials

Gastroenterology

Rob Dillard

Thyroid Dysfunction is Common in Women With Breast Cancer Following Radiation Therapy

Breast Cancer

Flagship Dataset Initially Released for T2D Markers and Factors

Diabetes

Latest News

Asymptomatic CRC Linked to Lower ctDNA Detection, Recurrence Risk Over Symptomatic Patients

Colorectal Cancer

Studies of ctDNA use in asymptomatic and symptomatic patients have demonstrated lower ctDNA detection in asymptomatic patients.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Career Center

Expert Interviews

Subscribe